Early-stage and small to midsize private and public companies in the life sciences sector began 2020 on a high note. Funding, particularly in the biotechnology sector, was pouring into the industry. Even several months into the pandemic, many biotech and other life sciences companies showed no signs of struggling to raise capital. But as COVID-19 continues to batter the world economy, life sciences leaders are likely to encounter new obstacles to funding growth....
Please see full publication below for more information.
